George Eldridge

George Eldridge is a seasoned financial executive with extensive experience in the biotechnology sector. Currently serving as Chief Financial Officer at Abcuro, Inc. since August 2025, Eldridge previously held the CFO position at Aerovate Therapeutics, Inc. from March 2021 to April 2025, where significant milestones included an IPO and a reverse merger following clinical challenges. Earlier roles include CFO at Lyndra Therapeutics, focused on innovative medication delivery systems, and at Sollis Therapeutics, which was advancing novel analgesic treatments. Eldridge's career in finance began at Proteon Therapeutics, where engagement in an IPO and subsequent merger characterized a dynamic period. Education includes an ABAB from Dartmouth College and an MBA from the University of Chicago.